NRx Pharmaceuticals, Inc. NRXP
At closeNov 3, 2026, 7:44 PM EST
After hours · Nov 3, 7:44 PM ET
- YTD
- -17.34%
- 1 year
- -21.40%
- Market cap
- 96.98M
- EPS (ttm)
- -0.58
- Shares out
- 12.09M
- Forward P/E
- -1.12
- YTD return
- -17.34%
- 1-year return
- -21.40%
- Volume
- 1.80M
- Avg volume
- 1.12M
- Open
- 2.17
- Previous close
- 2.17
- Day's range
- 2.11 – 2.34
- 52-week range
- 1.62 – 5.06
- Beta
- 1.27
- Price target
- 31.67 (+1313.7%)
- Earnings date
- Aug 14, 2024
1M -0.63 (-21.95%)
Key statistics
- Enterprise value
- 18.64M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -7.35M
- Total cash
- 1.90M
- Total debt
- 7.65M
- Return on equity
- 0.00%
- Short % of float
- 7.69%
- 50-day average
- 1.28
- 200-day average
- 2.53
Analyst view
- Target (low)
- 19.00
- Target (mean)
- 31.67
- Target (high)
- 45.00
- Strong buy1
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 14, 2024
Expected Aug 14, 2024. Consensus EPS estimate -0.295.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.81 | -0.15 | +0.66 | +81.48% |
| Aug 14, 2024 | Jun 1, 2024 | -0.81 | -0.75 | +0.06 | +7.41% |
| Aug 14, 2024 | Jun 1, 2024 | -0.81 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | 0.00 | -0.74 | — | — |
| May 14, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Mar 29, 2024 | Dec 1, 2023 | -0.70 | -0.50 | +0.20 | +28.57% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 2, 2024 | Ascendiant Capital | main | Buy | Buy |
| Nov 25, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 15, 2024 | D. Boral Capital | main | Buy | Buy |
| Oct 30, 2024 | EF Hutton | main | Buy | Buy |
| Oct 21, 2024 | EF Hutton | init | — | Buy |
| Sep 12, 2024 | Ascendiant Capital | main | Buy | Buy |
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- nrxpharma.com
News
Regeneron Pharmaceuticals To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Monday 
Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $51 
NRx Pharmaceuticals, Inc. (NRXP) Discusses FDA Approval of Preservative-Free Ketamine Transcript 
NRx Pharmaceuticals Wins FDA Approval for Preservative-Free Ketamine Injection 
12 Health Care Stocks Moving In Friday's Pre-Market Session 
NRx Pharmaceuticals Receives FDA Approval Of Its Abbreviated New Drug Application For Preservative-Free Ketamine 
NRx Pharmaceuticals (Nasdaq:NRXP) Receives FDA Approval of Preservative-Free Ketamine Ahead of November 10 FDA Goal Date 
Why Civeo Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket 
NRx Pharmaceuticals (NRXP) Stock Jumps Over 26% After Hours: What's Behind the Surge? 
NRx Pharmaceuticals (Nasdaq: NRXP) to Host Conference Call on October 30, 2026 to Discuss Regulatory Milestone for Preservative-Free Ketamine
Your note
Sign in to keep a note on NRXP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| GOROVITZ AARON | Director | Purchase | Aug 29, 2023 | 0 |
| HURVITZ CHAIM | Director | Purchase | Aug 29, 2023 | 2,214,790 |
| JAVITT JONATHAN C | Chairman of the Board | Purchase | Dec 16, 2024 | 1,516,830 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 1.99% | 240,316 | 341.25K | Sep 29, 2024 |
| Anson Funds Management LP | 1.18% | 142,525 | 202.38K | Sep 29, 2024 |
| AdvisorShares Investments, LLC | 1.08% | 130,085 | 184.72K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.64% | 77,341 | 109.82K | Sep 29, 2024 |
| Sabby Management, LLC | 0.29% | 35,049 | 49.77K | Sep 29, 2024 |
| Blackrock Inc. | 0.24% | 29,075 | 41.29K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AdvisorShares Trust-AdvisorShares Psychedelics ETF | 2.41% | 291,271 | 413.60K | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 1.60% | 193,423 | 274.66K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.39% | 46,893 | 66.59K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.36% | 43,510 | 61.78K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.09% | 10,327 | 14.66K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.08% | 10,005 | 14.21K | Oct 30, 2024 |